30
May

CTI BioPharma and its partner Baxter outlined positive Phase III data for their myelofibrosis drug pacritinib, which may help pave a way to position the therapy against Jakafi next year.

…read more

Source: ASCO: CTI’s myelofibrosis drug pacritinib posts competitive PhIII data

    

0 No comments